TIMI Study Group
@timistudygroup
Providing the latest news and research from the TIMI Study Group, an ARO affiliated with Brigham and Women’s Hospital and Harvard Medical School.
ID: 1854335850
http://www.timi.org 11-09-2013 13:41:01
1,1K Tweet
4,4K Takipçi
325 Takip Edilen
Starting #ESCCongress with excellent talk from Dr. Marc Sabatine TIMI Study Group on impact of #lipid and adipose tissue changes after #ACS
See the clinical outcomes in >10,000 Asian vs >61,000 Non-Asian race patients with AF randomized to warfarin vs DOACs: a patient-level meta-analyses from COMBINE AF, presented by Tze-Fan Chao tomorrow at 12:00 at Station 1. Robert Giugliano #ESCCongress
Rare cardiomyopathy-associated genetic variants are associated w/outcomes in AF pts. AF pts w/rare variants have more HF at dx, more HF-related hospital admissions & more cardiovascular death during follow-up. Genetic testing might affect prognosis. Nicholas Marston #ESCCongress
Dr. Samer Alsaid presents his meta-analysis on extracranial systemic embolic events in 71, 683 patients with atrial fibrillation randomized to NOAC vs warfarin in the COMBINE-AF study, tomorrow at 17:00 in Science Box 3 Robert Giugliano #ESCCongress
Dr. Manasi Tannu presents work on predictors and outcomes of intracranial hemorrhage in 58,000 patients with atrial fibrillation on oral anticoagulation: insights from COMBINE-AF, in 24 hrs in Science Box 2 Robert Giugliano #ESCCongress
See Yumi Kang, MD, PhD give her LBCT presentation on cardiovascular efficacy of evolocumab in patients with obesity from FOURIER (TIMI 59), tomorrow at 11:00 in Bishkek Michelle O'Donoghue Robert Giugliano #ESCCongress
See Paul M Haller's presentation on HF risk assessment using biomarkers from 32,041 patients in COMBINE-AF, tomorrow at 13:15 in Science Box 2 Robert Giugliano #ESCCongress
Shinwan Kany presents his work on exome sequencing in over 63,000 from TIMI trials, which reveals pathogenic cardiomyopathy variant carriers with high risk for heart failure and cardiovascular death. 24 hrs from now in Science Box 3 @marstonmd Shino Kany #ESCCongress
COMBINE-AF data from 71,683 patients shows SEE is 1/10th as common as ischemic stroke but carries similar mortality risk and often requires intervention. NOACs are superior to warfarin in SEE prevention Samer Alsaid Robert Giugliano #ESCCongress
More bang for your buck with #PCSK9i evolocumab in pts w/ obesity! Fantastic presentation of Yumi Kang, MD, PhD at #ESCCongress TIMI Study Group Robert Giugliano Michelle O'Donoghue
Evolocumab appears to attenuate the excess risk of MACE in patients with obesity. Yumi Kang, MD, PhD Michelle O'Donoghue Robert Giugliano #ESCCongress
In 32,000 AF pts from COMBINE-AF, cardiac #biomarkers sign.⤴️ #heartfailure risk prediction! hs-cTnT as important as NTproBNP pointing to a promising dual-marker strategy. Results simultaneously published in JACC Journals Paul M Haller Robert Giugliano #ESCCongress
Using exome seq in 63,700 pts from 5 TIMI CV outcome trials, we observed 866(1.3%) CMP variant carriers. These pts had ↑ rates of hospitalization for HF, incident AF & DCM variant carriers in particular of CV death over ~2.5 years of f/u. Nicholas Marston Shino Kany #ESCCongress
#ESCCongress #LBCT Among pts undergoing invasive procedures in #AZALEA-TIMI 71, low and comparable rates of peri-procedural 🩸🩸 in those randomized to long-acting #FXI inhibition with abelacimab vs. rivaroxaban. Sid M. Patel
A new analysis from the AZALEA study presented as an #ESCCongress late-breaker by Sid M. Patel w/ the TIMI Study Group found approx. 1% of pts taking abelacimab experienced a major or CRNM bleed while undergoing a procedure. 👉 bit.ly/3z0MiaO.
Recognition of preshock or early CS states is important to facilitate early identification, to guide appropriate triage and to enable prompt interventions aimed at delaying or preventing the onset of overt CS. bit.ly/3zeRsQn #JACCHF Sid M. Patel TIMI Study Group
